Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Spondyloarthritis
•
Psoriatic arthritis
•
General Rheumatology
•
Cardiology
•
Cardio-Rheumatology
•
Pericarditis
In a patient with psoriatic arthritis and recurrent pericarditis, would you combine abatacept or other biologics with rilonacept?
Related Questions
How do you approach cardiovascular risk management in patients with rheumatic disease?
Do you pursue coronary artery calcium scoring in patients with metabolic risk factors and autoimmune disease in order to guide decisions regarding GLP-1 medications?
How do you approach management of recurrent idiopathic pleuropericarditis?
For patients who do not have access to biologic therapies, what are some csDMARD combination pearls or tips that you have that have particular efficacy in different rheumatologic diseases?
What is your approach to differentiating tender spots (as in fibromyalgia) and enthesitis (as in axSpA)?
In a patient with isolated HLA B27+ anterior uveitis, how long would you continue immunosuppressive therapy?
Would you be hesitant to continue a TNF inhibitor in a patient with stable RA and a history of COPD, Cor Pulmonale, severe reduced RVEF, but LVEF 65%?
Would you switch to bimekizumab if a patient with psoriatic arthritis who is already on an IL-17 inhibitor has breakthrough skin or joint disease?
Are you comfortable with using NSAIDs in a patient on methotrexate for inflammatory arthritis?
How would you manage cardiac sarcoid with intolerance/contraindications to methotrexate, azathioprine, and mycophenolate/mycophenolic acid and that has proven refractory to adalimumab and infliximab as determined by PET?
